Selected References
- Brooks C, et al. 1977. Linear growth of children with limb deformities following exposure to thalidomide in utero. Acta Paediatr Scan 66:673-675.
- Castilla E, et al. 1996. Thalidomide, a current teratogen in South America. Teratology 54:273-277.
- Gao S, et al. 2020. Recent advances in the molecular mechanism of thalidomide teratogenicity. Biomed Pharmacother. ;127:110114. doi: 10.1016/j.biopha.2020.110114. Epub 2020 Apr 15.
- Gollop T, et al. 1987. Prenatal diagnosis of thalidomide syndrome. Prenat Diagn 7:295-298.
- Ito T, et al. 2020. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci.;96(6):189-203.
- Miller MT, et al. 2009. Thalidomide and misoprostol: Opthalmologic manifestations and associations both expected and unexpected. Birth Defects Res A Clin Mol Teratol. 85(8):667-676.
- Peng X, et al. 2017. Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients. Medicine (Baltimore) 96(21):e6540.
- Prescriber Guide to (THALOMID REMS™ ) Risk Evaluation and Mitigation Strategy (REMS)™ Program . (2014). Retrieved from https://www.fda.gov/media/79047/download
- Rodier PM, 2000. The Early Origins of Autism, Scientific American 282:56-63.
- Rodier PM. 2002. Converging evidence for brain stem injury in autism. Dev Psychopathol. ;14(3):537-57.
- Smithells R. 1992. Recognition of thalidomide defects. J Med Genet 29:716-723.
- Sterling D, et al. 1997. Thalidomide: a surprising recovery. J Am Pharm Assn 3:306-313.
- Stromland K, et al. 1993. Thalidomide embryopathy: revisited 27 years later. Acta Ophthalmol (Copen) 71:238-245.
